ELISA Kit for Vanin 1 (VNN1)

0.156-10ng/mL

The minimum detectable dose of this kit is typically less than 0.054ng/mL

3h

This assay has high sensitivity and excellent specificity for detection of Vanin 1 (VNN1).
No significant cross-reactivity or interference between Vanin 1 (VNN1) and analogues was observed.

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Vanin 1 (VNN1). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Vanin 1 (VNN1). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Vanin 1 (VNN1), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Vanin 1 (VNN1) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Vanin-1; a potential biomarker for nephrotoxicant-induced renal injury; Urinary vanin-1 as a novel biomarker for early detection of drug-induced acute kidney injury.; Effects of Exercise and Ferula Gummosa on Apelin of Cardiac and Kidney Tissues in L-NAME induced Hypertension in Rats; Value of vanin-1 assessment in adult patients with primary immune thrombocytopenia; Early detection of renal injury using urinary vanin-1 in rats with experimental colitis.; Early prediction of cisplatin-induced nephrotoxicity by urinary vanin-1 in patients with urothelial carcinoma;